Chemotherapy for Primary Central Nervous System Lymphoma

Macarena I De La Fuente, Antonio M. Omuro

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

In this chapter, commonly used chemotherapy regimens for primary central nervous system (CNS) lymphoma are discussed in the context of an overall approach to the disease. In the newly diagnosed setting, the mainstay of treatment remains methotrexate-based chemotherapy. Several effective multiagent methotrexate-based regimens have reported interesting results, although randomized studies are few. In the United States, the most common regimens are rituximab, procarbazine, vincristine, and cytarabine (R-MPV-A) and rituximab, methotrexate, temozolomide, cytarabine, and etoposide (R-MT-EA). Myeloablative chemotherapy regimens, particularly thiotepa, busulfan, and cyclophosphamide (TBC) followed by stem-cell transplant (ASCT) have emerged as powerful consolidation tools, although the optimal timing remains to be determined. The different available regimens will be discussed, with emphasis on efficacy and relative risks and benefits.

Original languageEnglish (US)
Title of host publicationHandbook of Brain Tumor Chemotherapy, Molecular Therapeutics, and Immunotherapy
Subtitle of host publicationSecond Edition
PublisherElsevier Inc.
Pages455-468
Number of pages14
ISBN (Print)9780128121009
DOIs
StatePublished - Apr 24 2018

Fingerprint

Methotrexate
Lymphoma
Central Nervous System
temozolomide
Cytarabine
Drug Therapy
Thiotepa
Procarbazine
Busulfan
Vincristine
Etoposide
Cyclophosphamide
Stem Cells
Transplants
Rituximab
Therapeutics

Keywords

  • Chemotherapy for Primary Intraocular Lymphoma
  • High-dose chemotherapy with autologous stem-cell transplantation
  • High-dose methotrexate (MTX)
  • Intrathecal chemotherapy
  • Primary central nervous system lymphoma (PCNSL)

ASJC Scopus subject areas

  • Medicine(all)
  • Neuroscience(all)

Cite this

De La Fuente, M. I., & Omuro, A. M. (2018). Chemotherapy for Primary Central Nervous System Lymphoma. In Handbook of Brain Tumor Chemotherapy, Molecular Therapeutics, and Immunotherapy: Second Edition (pp. 455-468). Elsevier Inc.. https://doi.org/10.1016/B978-0-12-812100-9.00035-8

Chemotherapy for Primary Central Nervous System Lymphoma. / De La Fuente, Macarena I; Omuro, Antonio M.

Handbook of Brain Tumor Chemotherapy, Molecular Therapeutics, and Immunotherapy: Second Edition. Elsevier Inc., 2018. p. 455-468.

Research output: Chapter in Book/Report/Conference proceedingChapter

De La Fuente, MI & Omuro, AM 2018, Chemotherapy for Primary Central Nervous System Lymphoma. in Handbook of Brain Tumor Chemotherapy, Molecular Therapeutics, and Immunotherapy: Second Edition. Elsevier Inc., pp. 455-468. https://doi.org/10.1016/B978-0-12-812100-9.00035-8
De La Fuente MI, Omuro AM. Chemotherapy for Primary Central Nervous System Lymphoma. In Handbook of Brain Tumor Chemotherapy, Molecular Therapeutics, and Immunotherapy: Second Edition. Elsevier Inc. 2018. p. 455-468 https://doi.org/10.1016/B978-0-12-812100-9.00035-8
De La Fuente, Macarena I ; Omuro, Antonio M. / Chemotherapy for Primary Central Nervous System Lymphoma. Handbook of Brain Tumor Chemotherapy, Molecular Therapeutics, and Immunotherapy: Second Edition. Elsevier Inc., 2018. pp. 455-468
@inbook{7aed214d5d5045cc9397d5bcca1ee223,
title = "Chemotherapy for Primary Central Nervous System Lymphoma",
abstract = "In this chapter, commonly used chemotherapy regimens for primary central nervous system (CNS) lymphoma are discussed in the context of an overall approach to the disease. In the newly diagnosed setting, the mainstay of treatment remains methotrexate-based chemotherapy. Several effective multiagent methotrexate-based regimens have reported interesting results, although randomized studies are few. In the United States, the most common regimens are rituximab, procarbazine, vincristine, and cytarabine (R-MPV-A) and rituximab, methotrexate, temozolomide, cytarabine, and etoposide (R-MT-EA). Myeloablative chemotherapy regimens, particularly thiotepa, busulfan, and cyclophosphamide (TBC) followed by stem-cell transplant (ASCT) have emerged as powerful consolidation tools, although the optimal timing remains to be determined. The different available regimens will be discussed, with emphasis on efficacy and relative risks and benefits.",
keywords = "Chemotherapy for Primary Intraocular Lymphoma, High-dose chemotherapy with autologous stem-cell transplantation, High-dose methotrexate (MTX), Intrathecal chemotherapy, Primary central nervous system lymphoma (PCNSL)",
author = "{De La Fuente}, {Macarena I} and Omuro, {Antonio M.}",
year = "2018",
month = "4",
day = "24",
doi = "10.1016/B978-0-12-812100-9.00035-8",
language = "English (US)",
isbn = "9780128121009",
pages = "455--468",
booktitle = "Handbook of Brain Tumor Chemotherapy, Molecular Therapeutics, and Immunotherapy",
publisher = "Elsevier Inc.",

}

TY - CHAP

T1 - Chemotherapy for Primary Central Nervous System Lymphoma

AU - De La Fuente, Macarena I

AU - Omuro, Antonio M.

PY - 2018/4/24

Y1 - 2018/4/24

N2 - In this chapter, commonly used chemotherapy regimens for primary central nervous system (CNS) lymphoma are discussed in the context of an overall approach to the disease. In the newly diagnosed setting, the mainstay of treatment remains methotrexate-based chemotherapy. Several effective multiagent methotrexate-based regimens have reported interesting results, although randomized studies are few. In the United States, the most common regimens are rituximab, procarbazine, vincristine, and cytarabine (R-MPV-A) and rituximab, methotrexate, temozolomide, cytarabine, and etoposide (R-MT-EA). Myeloablative chemotherapy regimens, particularly thiotepa, busulfan, and cyclophosphamide (TBC) followed by stem-cell transplant (ASCT) have emerged as powerful consolidation tools, although the optimal timing remains to be determined. The different available regimens will be discussed, with emphasis on efficacy and relative risks and benefits.

AB - In this chapter, commonly used chemotherapy regimens for primary central nervous system (CNS) lymphoma are discussed in the context of an overall approach to the disease. In the newly diagnosed setting, the mainstay of treatment remains methotrexate-based chemotherapy. Several effective multiagent methotrexate-based regimens have reported interesting results, although randomized studies are few. In the United States, the most common regimens are rituximab, procarbazine, vincristine, and cytarabine (R-MPV-A) and rituximab, methotrexate, temozolomide, cytarabine, and etoposide (R-MT-EA). Myeloablative chemotherapy regimens, particularly thiotepa, busulfan, and cyclophosphamide (TBC) followed by stem-cell transplant (ASCT) have emerged as powerful consolidation tools, although the optimal timing remains to be determined. The different available regimens will be discussed, with emphasis on efficacy and relative risks and benefits.

KW - Chemotherapy for Primary Intraocular Lymphoma

KW - High-dose chemotherapy with autologous stem-cell transplantation

KW - High-dose methotrexate (MTX)

KW - Intrathecal chemotherapy

KW - Primary central nervous system lymphoma (PCNSL)

UR - http://www.scopus.com/inward/record.url?scp=85054697973&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054697973&partnerID=8YFLogxK

U2 - 10.1016/B978-0-12-812100-9.00035-8

DO - 10.1016/B978-0-12-812100-9.00035-8

M3 - Chapter

SN - 9780128121009

SP - 455

EP - 468

BT - Handbook of Brain Tumor Chemotherapy, Molecular Therapeutics, and Immunotherapy

PB - Elsevier Inc.

ER -